


Understanding genotype phenotype relationships in human diseases using an **edgetic** approach


Georges Coppin^{1,2,3}, Anupama Yadav^{1,2}, Dylan Markey¹, David De Ridder¹, Kerstin Spirohn¹, Tong Hao¹, Jochen Weile^{3,4}, Atina Cote^{3,4}, Michael A. Calderwood^{1,2}, David E. Hill^{1,2}, Frederick P. Roth^{1,4,5,6}, Jean-Claude Twizere³, Marc Vidal^{1,2}

¹Center for Cancer Systems Biology (CCSB) and Department of Cancer Biology, DFCI, Boston, MA, ²Department of Genetics, Harvard Medical School, Boston, MA, ³Molecular Biology of Diseases, Groupe Interdisciplinaire de Génomique Appliquée (GIGA) and Laboratory of Viral Interactomes, University of Liège, Liège, Belgium, ⁴Donnelly Centre, University of Toronto, Toronto, Canada, ⁵LTRI, Mount Sinai Hospital, Toronto, Canada, ⁶Department of Molecular Genetics and Computer Science, University of Toronto, Toronto, Canada



Drastic increase in variants of uncertain significance (VUS)^{1,2}




Highly skewed literature coverage of disease genes



Urgent need to functionally and molecularly characterize variants in disease genes



Network based approach to understand genotype phenotype relationships



High throughput cloning of disease alleles

Variant selection: Disease variant archives (Clinvar, HGMD), Diverse populations (1000 genomes, ExAC), Specific disease cohorts (Parkinsons, Asthma-COPD).

Cloning: pEXPAD Spec, PCR, Tail1, Tail2, Tail3, Tail4, Tail5, Tail6, Tail7, Tail8, Tail9, Tail10, Tail11, Tail12, Tail13, Tail14, Tail15, Tail16, Tail17, Tail18, Tail19, Tail20, Tail21, Tail22, Tail23, Tail24, Tail25, Tail26, Tail27, Tail28, Tail29, Tail30, Tail31, Tail32, Tail33, Tail34, Tail35, Tail36, Tail37, Tail38, Tail39, Tail40, Tail41, Tail42, Tail43, Tail44, Tail45, Tail46, Tail47, Tail48, Tail49, Tail50, Tail51, Tail52, Tail53, Tail54, Tail55, Tail56, Tail57, Tail58, Tail59, Tail60, Tail61, Tail62, Tail63, Tail64, Tail65, Tail66, Tail67, Tail68, Tail69, Tail70, Tail71, Tail72, Tail73, Tail74, Tail75, Tail76, Tail77, Tail78, Tail79, Tail80, Tail81, Tail82, Tail83, Tail84, Tail85, Tail86, Tail87, Tail88, Tail89, Tail90, Tail91, Tail92, Tail93, Tail94, Tail95, Tail96, Tail97, Tail98, Tail99, Tail100.

18,000 variants in > 2,100 genes

Highly versatile gateway cloning system⁸: Gateway cloning system for high-throughput cloning of DNA fragments into a common vector.

Clones are sequence confirmed using long read sequencing to ensure a single nucleotide change

At least one allele cloned for 40 percent of diseases

Cloned alleles uniformly spread across disease categories

Allows testing of multiple molecular interactions and phenotypes⁹

Disease categories from MeSH

Different perturbation patterns of disease, uncertain and benign variants

Interaction perturbed by mutation vs **Interaction unperturbed by mutation**

Quasi-wild-type (QW) vs **Quasi-null (QN)** vs **Edgetic (E)**

Direct association between edge perturbation and pathogenicity

Edgetic profiles of variants in MLH1 Interactors

Clinvar is systematically reannotating genetic variants based on emerging data and expert panels¹. Some variants, considered pathogenic in 2015 by Clinvar and HGMD, have been reannotated to VUS or conflicting.

The ratio of interaction perturbation (QN + E) is directly correlated with pathogenicity.

~30,000 edges involving disease genes in the systematic human reference protein interactome

Literature-curated interactome vs **Systematic human reference interactome (HI-III)**

Human genes ranked by number of publications

70,000 protein-protein interactions (PPIs) between 17,500 proteins¹⁰.

Interactions validated by sequencing and other orthogonal assays.

Uniform, unbiased coverage of the human genome^{10,11}.

30,000 PPIs involving 50% of disease genes.

Tissue specificity of diseases caused by uniformly expressed genes

"One" genome vs **30+ tissue transcriptomes** vs **30+ tissues**

Most of the Mendelian diseases are tissue specific.

For >80% of tissue specific diseases, not a single causal gene is expressed preferentially in the diseased tissue¹⁰.

Model: Variants in uniformly expressed-genes might cause tissue specific diseases by perturbing interactions with tissue specific genes.

Constructing tissue specific interactome

Edgetic effects of variants in uniformly expressed genes causing tissue specific diseases¹⁰

Systematic human reference interactome (HI-III) uniformly covers diseases genes

Literature-curated interactome vs **HI-III** vs **HI-III with cloned alleles**

Number of publications vs **Number of PPIs**

Edgetic effects of variants in uniformly expressed genes causing tissue specific diseases¹⁰

Brain vs **Basal ganglia** vs **Cerebellum** vs **Brain other**

PKNP WT vs **Pro20Ser** vs **Glu326Lys**

Tissue-preferential expression value